Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Disease × Mitomycin × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Non-Muscle Invasive Bladder Neoplasms 13 Carcinoma, Transitional Cell 11 Urinary Bladder Neoplasms 10 Carcinoma 3 Recurrence 2 Neoplasms 2 Virus Diseases 1 Urologic Neoplasms 1 Urogenital Neoplasms 1 Neoplasms by Site 1 Neoplasms by Histologic Type 1 Disease 1 Carcinoma, Hepatocellular 1 Carcinoma in Situ 1 Adenoviridae Infections 1

Interventions

fluciclovine F-18 2 Positron-Emission Tomography 2 Injections 2 Dexamethasone 2 tislelizumab 1 ricolinostat 1 pomalidomide 1 pembrolizumab 1 gossypol acetic acid 1 daratumumab 1 aflibercept 1 Prednisone 1 Oncolytic Virotherapy 1 Octreotide 1 Mitomycin 1 Mammography 1 Lenalidomide 1 Ipilimumab 1 Drug Delivery Systems 1 Docetaxel 1 Diagnosis, Computer-Assisted 1 Daunorubicin 1 Cytarabine 1 Control Groups 1 CPX-351 1 Bevacizumab 1 Antibodies, Monoclonal 1 3-Iodobenzylguanidine 1 3-(1-benzenesulfonyl-2,3-dihydro-1H-indol-5-yl)-N-hydroxyacrylamide 1 2-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03335059 2020-04-15

RITE-USA

Medical Enterprises Ltd.

Phase 3 Terminated

Urinary Bladder Neoplasms, Disease

Data powered by HemOnc (CC BY 4.0) Colophon ⚡